OTCMKTS:IMUCD

ImmunoCellular Therapeutics Competitors

$0.48

-0.03 (-5.88 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.48

Now: $0.48▼

$0.51

50-Day Range

$0.31

MA: $0.60▼

$0.87

52-Week Range

$0.16

Now: $0.48▼

$0.51

Volume7,298 shs

Average Volume6,605 shs

Market Capitalization$2.01 million

P/E RatioN/A

Dividend YieldN/A

Beta1.63

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Vs. GBIM, PARNF, PVTTF, WCUI, KAYS, and ISCO

Should you be buying IMUCD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ImmunoCellular Therapeutics, including GlobeImmune (GBIM), Parnell Pharmaceuticals (PARNF), Pivotal Therapeutics (PVTTF), Wellness Center USA (WCUI), Kaya (KAYS), and International Stem Cell (ISCO).

ImmunoCellular Therapeutics vs. GlobeImmune Stock

GlobeImmune (OTCMKTS:GBIM) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for GlobeImmune and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlobeImmune	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Earnings and Valuation

This table compares GlobeImmune and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlobeImmune	N/A	N/A	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

Volatility and Risk

GlobeImmune has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Profitability

This table compares GlobeImmune and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlobeImmune	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	N/A

Summary

GlobeImmune beats ImmunoCellular Therapeutics on 1 of the 1 factors compared between the two stocks.

ImmunoCellular Therapeutics vs. Parnell Pharmaceuticals Stock

Parnell Pharmaceuticals (OTCMKTS:PARNF) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Parnell Pharmaceuticals and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parnell Pharmaceuticals	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Profitability

This table compares Parnell Pharmaceuticals and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parnell Pharmaceuticals	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Parnell Pharmaceuticals and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parnell Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

Volatility and Risk

Parnell Pharmaceuticals has a beta of 5, suggesting that its share price is 400% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

Parnell Pharmaceuticals beats ImmunoCellular Therapeutics on 1 of the 1 factors compared between the two stocks.

ImmunoCellular Therapeutics vs. Pivotal Therapeutics Stock

Pivotal Therapeutics (OTCMKTS:PVTTF) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pivotal Therapeutics and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pivotal Therapeutics	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Profitability

This table compares Pivotal Therapeutics and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pivotal Therapeutics	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Pivotal Therapeutics and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pivotal Therapeutics	N/A	N/A	N/A	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

Volatility & Risk

Pivotal Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Pivotal Therapeutics on 1 of the 1 factors compared between the two stocks.

ImmunoCellular Therapeutics vs. Wellness Center USA Stock

Wellness Center USA (OTCMKTS:WCUI) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Wellness Center USA and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wellness Center USA	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Profitability

This table compares Wellness Center USA and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Wellness Center USA	N/A	N/A	-1,809.19%
ImmunoCellular Therapeutics	N/A	N/A	N/A

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are owned by institutional investors. 14.1% of Wellness Center USA shares are owned by company insiders. Comparatively, 3.3% of ImmunoCellular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Wellness Center USA and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wellness Center USA	$30,000.00	228.21	$-2,390,000.00	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

Wellness Center USA has higher revenue and earnings than ImmunoCellular Therapeutics.

Risk & Volatility

Wellness Center USA has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Summary

Wellness Center USA beats ImmunoCellular Therapeutics on 4 of the 6 factors compared between the two stocks.

ImmunoCellular Therapeutics vs. Kaya Stock

Kaya (OTCMKTS:KAYS) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Kaya and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kaya	$1.01 million	6.71	$7.80 million	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

Kaya has higher revenue and earnings than ImmunoCellular Therapeutics.

Profitability

This table compares Kaya and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kaya	-1,558.07%	N/A	-586.93%
ImmunoCellular Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Kaya and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kaya	0	1	0	0	2.00
ImmunoCellular Therapeutics	0	0	0	0	N/A

Volatility & Risk

Kaya has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Kaya on 3 of the 5 factors compared between the two stocks.

ImmunoCellular Therapeutics vs. International Stem Cell Stock

International Stem Cell (OTCMKTS:ISCO) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares International Stem Cell and ImmunoCellular Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Stem Cell	$9.47 million	0.57	$-4,260,000.00	N/A	N/A
ImmunoCellular Therapeutics	N/A	N/A	$-14,310,000.00	N/A	N/A

International Stem Cell has higher revenue and earnings than ImmunoCellular Therapeutics.

Profitability

This table compares International Stem Cell and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
International Stem Cell	-55.56%	N/A	-72.21%
ImmunoCellular Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations for International Stem Cell and ImmunoCellular Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
International Stem Cell	0	0	0	0	N/A
ImmunoCellular Therapeutics	0	0	0	0	N/A

Volatility & Risk

International Stem Cell has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats International Stem Cell on 3 of the 5 factors compared between the two stocks.